Recombinant snakebite antivenoms: A cost-competitive solution to a neglected tropical disease?
Recombinant snakebite antivenoms: A cost-competitive solution to a neglected tropical disease?
复制标题
DOI：
10.1371/journal.pntd.0005361
复制
发表时间：
2017-02-01
影响因子：
3.8
通讯作者：
Andersen, Mikael R.
中科院分区：
文献类型：
--
作者：
Laustsen, Andreas H.;Johansen, Kristoffer H.;Andersen, Mikael R.
蛇咬伤是发展中国家热带地区的主要公共卫生负担。在撒哈拉以南非洲地区，忽视导致了抗蛇毒血清的短缺，威胁着蛇咬伤受害者的生命和四肢。抗蛇毒血清领域的技术进步是必要的，但不仅应评估其可能的治疗影响，还应评估其成本竞争力。基于 CHO 细胞培养产生的人 IgG 抗体寡克隆混合物的重组抗蛇毒血清可能是获得更好的蛇咬伤毒疗法的关键。根据行业数据，使用重组抗蛇毒血清治疗蛇咬伤的最终药品成本估计在 60-250 美元之间。据报道，目前市场上一种有效的抗蛇毒血清（来自南非疫苗生产商的 SAIMR 蛇多价抗蛇毒血清）的批发价为每次蛇咬伤治疗 640 美元。因此，重组抗蛇毒血清在未来可能成为现有血清抗蛇毒血清的一种具有成本竞争力的替代品。
Snakebite envenoming is a major public health burden in tropical parts of the developing world. In sub-Saharan Africa, neglect has led to a scarcity of antivenoms threatening the lives and limbs of snakebite victims. Technological advances within antivenom are warranted, but should be evaluated not only on their possible therapeutic impact, but also on their cost-competitiveness. Recombinant antivenoms based on oligoclonal mixtures of human IgG antibodies produced by CHO cell cultivation may be the key to obtaining better snakebite envenoming therapies. Based on industry data, the cost of treatment for a snakebite envenoming with a recombinant antivenom is estimated to be in the range USD 60-250 for the Final Drug Product. One of the effective antivenoms (SAIMR Snake Polyvalent Antivenom from the South African Vaccine Producers) currently on the market has been reported to have a wholesale price of USD 640 per treatment for an average snakebite. Recombinant antivenoms may therefore in the future be a cost-competitive alternative to existing serum-based antivenoms.